Brief: Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To Metavia
18/11/2024 13:19
Nov 18 (Reuters) - Neurobo Pharmaceuticals Inc NRBO.O :
* NEUROBO PHARMACEUTICALS INC: STRATEGIC REALIGNMENT AHEAD
OF
IMPORTANT CLINICAL MILESTONES WITH NAME CHANGE TO METAVIA
* NEUROBO PHARMACEUTICALS INC: COMMON STOCK WILL BEGIN
TRADING ON
NASDAQ UNDER "MTVA," WHICH IS EXPECTED TO BE OPERATIVE AS OF
NOVEMBER 29
Source text: ID:nPn6xp64za
Further company coverage: NRBO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MetaVia
See all newsMetaVia Inc reports results for the quarter ended June 30 - Earnings Summary
MetaVia Q2 net loss widens on higher R&D spending
MetaVia Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
MetaVia Q1 net loss widens slightly as expenses rise